DSIP: What It Is Studied Alongside
Delta sleep-inducing peptide (DSIP) is a research peptide studied alongside blood-brain barrier transport sequences, neurotransmitter models, and peptide synthesis chemistry. This page summarises the published evidence a
Delta sleep-inducing peptide (DSIP) is a short endogenous peptide, also referred to in the literature as delta sleep-inducing peptide or by the abbreviation DSIP. It is classified as a neuropeptide and is studied in laboratory research settings. The evidence block for this page does not supply a sequence, molecular formula, or molecular weight for DSIP, so none is stated here. Where the compound appears in the supplied evidence, it appears as a component of fusion peptides rather than as an isolated entity.
The work summarised on this page centres on blood-brain barrier transport and on neurotransmitter balance in a rodent insomnia model, alongside peptide synthesis chemistry that is relevant to how such peptides are produced.
Research Studies
DSIP and blood-brain barrier crossing in a PCPA-induced insomnia mouse model
The most directly relevant study in the evidence block examined delta sleep-inducing peptide in the form of DSIP-CBBBP fusion peptides, produced by secretion from Pichia pastoris. The fusion constructs combined DSIP with blood-brain barrier crossing peptides. The researchers used a p-chlorophenylalanine (PCPA)-induced insomnia model in mice, a method described in the paper as akin to traditional approaches for evaluating sleep-promoting activity in fusion peptides [1].
The stated aim was to clarify the sleep-promoting mechanism of DSIP-CBBBP, to explore its impact on neurotransmitter levels and sleep regulation, and to analyse its composition and structure [1]. This is an animal model. No human data are reported in the supplied evidence, and no dose, route, or outcome measure for human use is provided.
DSIP and neurotransmitter balance in the same model
The same study frames its investigation around neurotransmitter balancing effects as a property of interest for DSIP-CBBBP fusion peptides [1]. The evidence block does not report specific neurotransmitter values, effect sizes, or statistical results, so no such figures are given here. What can be stated is that neurotransmitter level was one of the parameters the authors set out to examine in the PCPA-induced insomnia mouse model [1].
DSIP and sleep regulation endpoints
Sleep regulation is named in the evidence block as an area the DSIP-CBBBP work sought to address, alongside neurotransmitter levels [1]. The model used was PCPA-induced insomnia in mice [1]. This is animal-only evidence. The supplied material does not describe sleep architecture measurements, electroencephalographic endpoints, or any human sleep study.
DSIP and peptide structure analysis
Composition and structure analysis of the DSIP-CBBBP fusion peptides was listed among the aims of the study [1]. The evidence block does not reproduce the structural data, so no sequence or conformational detail is asserted on this page. Researchers interested in the structural characterisation should consult the primary paper directly.
DSIP and N-to-C peptide synthesis chemistry
A separate line of work in the evidence block concerns peptide synthesis methodology rather than DSIP biology. That paper reports an alternative N-to-C elongation strategy using catalytic peptide thioacid formation and oxidative peptide bond formation with main chain-unprotected amino acids under aerobic conditions [2]. The authors note that traditional chain-elongation from C- to N-terminus is reliable but generates large quantities of chemical waste from protecting groups and condensation reagents [2]. The method is described as applicable to iterative peptide couplings and conjugations [2]. This is in vitro chemistry. It is not a study of DSIP in a biological system, and it is included here because it bears on how peptides of this class are assembled in the laboratory.
DSIP and the naming collision with deuterium stable isotope probing
Two items in the evidence block use the abbreviation DSIP to mean deuterium stable isotope probing, not delta sleep-inducing peptide. One reports the applicability of deuterium stable isotope probing combined with Raman spectroscopy for sensing bactericidal and bacteriostatic antimicrobial modes of action in Escherichia coli [3]. A related preprint reports the same approach, describing bacteriostatic mode as arrested cell growth and bactericidal mode as cell death [4]. These are microbiology method papers. They are not studies of delta sleep-inducing peptide, and they should not be cited as such. They are noted here only to flag the abbreviation overlap for anyone searching the literature.
DSIP and unrelated uses of the same acronym in data and imaging research
Further items in the evidence block use DSIP as an acronym in entirely different fields. One describes a federated policy-governed architecture for sovereign European data spaces, addressing trusted and interoperable data sharing across organisational boundaries [5]. Another concerns domain-specific information preservation for Alzheimer's disease diagnosis with incomplete multi-modality neuroimages, where missing modality data poses a challenge in clinical practice [6]. Neither has any relationship to delta sleep-inducing peptide. They are listed in the sources for completeness of the evidence block and to make the acronym confusion explicit.
Comparison of evidence types across the supplied sources
The table below sets out what kind of evidence each supplied source represents, so that the strength and relevance of each can be judged at a glance.
| Source | Subject | Evidence type | Relevance to DSIP the peptide |
|---|---|---|---|
| [1] | DSIP-CBBBP fusion peptides | Animal model (PCPA-induced insomnia, mice) | Direct |
| [2] | N-to-C peptide synthesis | In vitro chemistry | Methodological |
| [3] | Deuterium stable isotope probing | Microbiology method | None — acronym overlap |
| [4] | Deuterium stable isotope probing | Microbiology method (preprint) | None — acronym overlap |
| [5] | European data spaces | Policy architecture | None — acronym overlap |
| [6] | Alzheimer's disease imaging | Computational neuroimaging | None — acronym overlap |
What the evidence does not establish
The supplied evidence does not provide a human dose, a human route of administration, or any human outcome for DSIP or its fusion peptides. It does not provide pharmacokinetic parameters in humans. It does not provide a sequence, molecular formula, or molecular weight for DSIP. It does not report specific neurotransmitter concentrations or sleep endpoint values. Any claim beyond what is listed above would not be supported by the material available for this page.
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page should be read as such. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models — https://europepmc.org/article/PMC/PMC11498945
- [2] Practical N-to-C peptide synthesis with minimal protecting groups — https://europepmc.org/article/PMC/PMC10603086
- [3] Sensing the Bactericidal and Bacteriostatic Antimicrobial Mode of Action Using Raman Deuterium Stable Isotope Probing (DSIP) in Escherichia coli — https://europepmc.org/article/PMC/PMC11154948
- [4] Sensing the bactericidal and bacteriostatic antimicrobial mode of action using Raman-Deuterium stable isotope probing (DSIP) — https://doi.org/10.1101/2024.02.12.579891
- [5] A federated policy-governed architecture for sovereign European data spaces — https://doi.org/10.12688/openreseurope.24687.1
- [6] Domain-specific information preservation for Alzheimer's disease diagnosis with incomplete multi-modality neuroimages — https://pubmed.ncbi.nlm.nih.gov/39798527/